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Parkinson’s disease (PD) is a neurodegenerative disease characterized by a speciﬁc loss of dopaminergic neurons. Although the
vast majority of PD cases are idiopathic in nature, there is a subset that contains genetic links. Of the genes that have been linked
to PD, α-synuclein and leucine-rich repeat kinase 2 have been used to develop transgenic rat models of the disease. In this paper
we focused on the various transgenic rat models of PD in terms of their ability to mimic key symptoms of PD in a progressive
manner. In general, we found that most of these models provided useful tools for the early stages of PD, but the development of
new transgenic rats that present signiﬁcant neuropathologic and motoric deﬁcits in a progressive manner that more accurately
mimics PD is needed.
1.Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder. It is hypothesized that PD is
caused by a combination of genetic and environmental
factors. A speciﬁc loss of dopaminergic (DA) neurons in the
substantia nigra (SN) in PD results in the signiﬁcant loss
of DA innervation of the neostriatum via the nigrostriatal
pathway. The progressive loss of this DA innervation, in
turn, is responsible for the characteristic motor symptoms
of PD, which include akinesia, resting tremors, and postural
instability.
A hallmark histopathological marker for PD is the pres-
ence of cytoplasmic inclusions, known as Lewy bodies (LBs),
which are found throughout the mesencephalon of the
PD brain, including the substantia nigra [1]. The major
component of LBs is the presynaptic protein called α-
synuclein (α-syn) [2]. To date, it is not known whether the
mechanismsunderlyingtheformationofLBsarethecauseor
aconsequenceofthedisease.SomefamilialformsofPDhave
been linked to mutations in genes that code for α-syn, as well
as genes that code for leucine-rich repeat kinase 2 (LRRK2),
DJ-1, and Parkin [3, 4]. These mutations have formed the
basis of developing transgenic rodent models of PD.
Presently, the only treatments for PD are palliative in
nature and usually utilize dopamine agonists, such as lev-
odopa (L-DOPA). Surgical techniques, such as pallidotomies
anddeep-brainstimulation,havealsoprovedtobesuccessful
in reducing some of the major motor symptoms of PD.
To date, the most promising avenue of research aimed at
restoring lost function in PD appears to be cell therapies,
and much of the recent research eﬀorts in this domain have
focused on use of stem cells.
However, signiﬁcant advances in developing eﬀective
therapies for PD have been limited by the lack of a valid
animal model that closely mimic the progressive neu-
ropathology and behavioral deﬁcits of PD. Most research
on PD has utilized rodents that are given speciﬁc neuro-
toxins, including 6-hydroxydopamine (6-OHDA), 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat, and2 Parkinson’s Disease
Table 1: Summary of studies using genetic rat models of PD. Note that % cell loss SNpc is percentage of cell loss in the substantia nigra,
pars compacta, relative to number of cells in the intact, untreated controls; “n.a.” indicates data for percentage loss of SNpc cells was not
available; plus sign (+) indicates signiﬁcant diﬀerences and “n.s.” indicates non-signiﬁcant diﬀerences between genetically altered rats and
wild-type controls on measures of protein aggregation or behavioral deﬁcits (i.e., stimulant-induced rotational activity, paw placement in
cylinder task, and/or spontaneous motor activity in open-ﬁeld).
Gene Method Percentage of
cell loss SNpc
Protein
aggregation Behavior deﬁcit Author year
hα-syn, α-syn A53T rAAV 30%–80% + + (in 25% of animals) Kirik et al. 2002 [12]
hα-syn A30P rAAV 53% + n.s. Klein et al. 2002 [13]
hα-syn A30P HIV-1 Lentivirus 33% + None performed Lo Bianco et al. 2002 [14]
hα-syn A53T HIV-1 Lentivirus 24% + None performed Lo Bianco et al. 2002 [14]
hα-syn rAAV 50% + n.s. Yamada et al. 2004 [15]
hα-syn rAAV2/5 40–60% + None performed Gorbatyuk etal. 2008 [16]
hα-syn S129A rAAV2/5 66–70% + None performed Gorbatyuk etal. 2008 [16]
hα-syn S129D rAAV2/5 n.a. + None Performed Gorbatyuk et al. 2008 [16]
hα-syn rAAV2/6 11–22% + None Performed da Silveira et al. 2009 [17]
hα-syn A30P rAAV2/6 11–22% + None Performed da Silveira et al. 2009 [17]
hα-syn WT S129A rAAV2/6 over 70% + None Performed da Silveira et al. 2009 [17]
hα-syn WT S129D rAAV2/6 n.a. + None Performed da Silveira et al. 2009 [17]
hα-syn A30P S129A rAAV2/6 over 70% + None Performed da Silveira et al. 2009 [17]
hα-syn A30P S129D rAAV2/6 n.s. + None Performed da Silveira et al. 2009 [17]
hα-syn A30P TAT 21.3–31.3% n.s. + Recchia et al. 2008 [18]
hα-syn A30P A53T Microinjection n.a. n.s. + Lelan et al. 2011 [19]
LRRK2 G2019S Rad 21.4% n.s. None Performed Dusonchet et al. 2011 [20]
LRRK2 G2019S TRE-tTA 0% n.s. + Zhou et al. 2011 [21]
rotenone, that are administrated into the substantia nigra
pars compacta (SNpc) or nigrostriatal pathway. Although
these models have yielded valuable insights into potentially
useful therapies for PD, they do not accurately mimic the full
constellation of neuropathological and behavioral deﬁcits
associated with PD. Recently, transgenic animal models of
PD have been developed by inserting the mutated human
gene in rodents. Although most of these transgenic models
have been developed in mice, more recent eﬀorts have
focused on developing transgenic rat models of PD.
The purpose of this paper is to provide an update
on the newly developed genetic rat models of PD and to
provide some assessment of their usefulness in therapeutic
research. We will attempt to compare each of the newly
developed models in terms of their ability to mimic both the
neuropathological and behavioral features of the disease (see
Table 1). We will also describe some of the early therapeutic
research using these models. Although none of these models
provide the optimal tool for testing potential treatments for
PD, we think that some of these models have the potential
to provide an improvement over the more commonly used
neurotoxic rat models.
2. α-SynucleinRatModels
The most thoroughly studied transgenic rat model of PD
is the α-synuclein rat model. As indicated previously, some
f a m i l i a lf o r m so fP Dh a v eb e e nl i n k e dt oα-syn, a small
neuronal 140 amino acid protein (14.4kDa) [5], that is
located in presynaptic terminals. In humans, the gene for
α-syn is located on chromosome 4q21-q23 [6] and this
protein is highly expressed in the brain. Missense autosomal
dominant mutations at A53T [7], E46K [8], and A30P [9]
of the gene-coding region of α- s y nh a v eb e e nl i n k e dt oL B
aggregates and Lewy neurites in patients with rare, early
onsetPD.Thepresynapticpresenceofα-synsuggestsarolein
synaptic vesicle traﬃcking. It has been shown that α-syn is a
dose-dependent inhibitor of tyrosine hydroxylase (TH) [10].
On the other hand, α-syn could be a link in the dopamine
transporter and, in this way, increase dopamine reuptake
[11]. As such, it appears that an optimal level of α-syn may
be critical for proper functioning of DA neurons.
Transgenic α-syn models have been created in adult rats
utilizing adenoassociated virus (rAAV) or HIV-1-derived
lenti-virus to transduce mutated human α-syn genes into
the nigrostriatal pathway. Also, HIV TAT-mediated protein
transduction has been used to transduce mutated human
α-syn protein. Although there has been some success with
achieving expression of α-syn in DA neurons within the
SN, the amount of DA neuronal degeneration varied greatly
between studies assessed by TH immunohistochemistry
(IHC).Someofthisvariationcouldbeduetodiﬀering forms
of the α-syn gene used, the method of delivery utilized,
or the gene promoter used. For example, Klein et al. [13]
found a 53% reduction of TH-positive DA neurons when
they injected rAAV expressing the mutant human α-syn
A30P into the SN, while Kirik et al. [12] reported a 30–80%
reduction when they injected rAAV expressing the mutantParkinson’s Disease 3
human α-synA53TintheSN.Kleinetal.[13]andK iriketal.
utilized a hybrid cytomegalovirus (CMV)/chicken β-actin
(CBA) promoter to drive expression of the diﬀering mutant
α-syn genes. This speciﬁc promoter is the CBA promoter
with enhancer elements from the CMV promoter added. In
addition, Kirik et al. [12] found a 50% reduction in TH
positiveDAstriatalinnervationateightweeksafterinjection.
In term of behavior, Kirik et al. [12] reported that 25% of
the α-syn-injected rats were impaired during apomorphine-
induced rotation assessments and on a paw-reaching (i.e.,
cylinder) task, an impairment that is compatible to a loss
of more than 60% of DA SN neurons. However, Klein
et al. [13] did not ﬁnd a signiﬁcant behavioral impair-
ment in amphetamine-induced rotations. Both Kirik and
Klein groups of investigators reported progressive pattern
of neurodegeneration that included α-syn aggregates that
resembled LBs in PD patients. As such, these transgenic rat
models of PD more closely mimicked the progressive loss
of dopaminergic neurons in PD than do the neurotoxic rat
models of this disease.
Yamada et. al [15] created an α-syn model using rAAV,
but utilized a cytomegalovirus (CMV) promoter which
diﬀered from the CMV/CBA promoter used by the Kirik
and Klein groups [12, 13]. Yamada et al. reported a 50%
decrease in the number of DA neurons in the injected SN,
but this decrease was insuﬃcient to produce signiﬁcant
diﬀerences between the injected rats and controls when these
animals were assessed on measures of apomorphine-induced
rotation.
Recchia et al. [18] created an α-syn model of PD by
administering intranigral injections of the A30P mutated
form of α-syn, fused to a TAT fusion protein. Their study
compared unilateral injections of TAT-α-syn A30P protein,
α-syn A30P protein, 6-OHDA, and sham controls into the
SN at various time points. Neurodegeneration and genetic
expression were assessed via IHC, western blot, HPLC
analysis, and behavioral assessment. They found that the α-
syn A30P protein, without the TAT fusion protein, did not
integrate within neurons of the SN, whereas 80% of TH-
positive cells were found to express α-syn A30P following
TAT-α-syn A30P injection. No formations of LBs or Lewy
neurites were found in these animals. The TAT-α-syn A30P
distribution, assessed by western blot, was found within
the SN, striatum, and contralateral cortex at 24 hours after
injection. At 15 and 30 days post-injection, the TAT-α-
syn A30P produced a 26.3 ± 5.0% loss in TH positive
neurons, compared to the 81.2 ± 2.1% loss in TH positive
neurons following the 6-OHDA injections. At 7 days post-
injection, the TAT-α-syn A30P animals showed a 20.8 ±
3.6% reduction in DA and 16.6 ± 2.5 %r e d u c t i o ni n3 , 4 -
dihydroxyphenylacetic acid (DOPAC) within the ipsilateral,
compared to the contralateral, striatum. In comparison,
the animals receiving 6-OHDA injections showed a 60.6 ±
3.6% reduction in DA and a 59.7% ± 4.5r e d u c t i o ni n
DOPAC within the ipsilateral, compared to the contralateral,
striatum. Administration of apomorphine did not produce a
signiﬁcant number of ipsilateral rotations in animals receiv-
ing TAT-α-syn A30P injections. However, rats receiving TAT-
α-syn A30P injections showed increasing motor impairment
at day 30 and day 90 when motor function was accessed via
rotorod and footprint analysis.
More recently, Sanchez-Guajardo et al. [22] studied the
temporal proﬁle of microglia activation in an α-syn rat
model of PD. They injected rAAV2/5 expressing human wild
type (hWT) α-syn directly into the right SN. Rats were
divided into two groups based upon the concentration of
rAAV2/5 hWT α-syn. The α-syn neurodegeneration group
received a lower concentrationof rAAV2/5 hWTα-syn, while
the α-syn cell-death group received a greater concentration.
The α-syn neurodegeneration rats did not exhibit a sig-
niﬁcant reduction in TH-positive neurons within the SN.
However, a decrease in TH-positive ﬁber density within
the striatum and pathological formations were observed
in these animals. The α-syn cell-death group exhibited a
signiﬁcant reduction in TH-positive neurons within the SN
and a reduction of TH-positive ﬁber density within the
striatum. An increase in microglia was seen in both groups
at four weeks after injection. The activated microglia was
signiﬁcantly higher in the neurodegeneration group at 4
weeks, and the levels of microglia returned to control levels
at 8–15 weeks. Within the cell-death group, microglia levels
peaked at 8 weeks and returned to control levels at 15 weeks.
Lelan et al. [19] created a transgenic α syn rat utilizing
microinjectiontotransfertheconstructpUTHTVexpressing
the A30P and A53T double-mutated human α syn under the
control of the rat TH promoter. These investigators observed
the expression of mutated human α-syn in olfactory bulbs
and within SN. They also observed an olfactory impairment
in mutated human α syn transgenic rats, when compared
to wild type rats. No impairment in motor behavior was
observed.
Gorbatyuketal.[16]createdthreeα-synmodelswiththe
hWT α-syn or mutated α-syn with S129A, or S129D muta-
tions. Unilateral injections of rAVV2/5 vectors expressing the
transgenes were done in the SN. Histological examinations
were carried out at 4, 8, or 26 weeks after injection. At 4
weeks,a70%lossinTH-positiveneuronswasobservedinthe
rats receiving S129A, whereas all other groups did not show
a signiﬁcant TH-positive neuronal loss, when compared to
controls. At 8 weeks, rats receiving an injection of WT α-syn
rats exhibited a 40% loss of TH-positive neurons and S129A
α-syn rats exhibited a 66% loss of TH neurons. However, rats
receiving hWT α-syn exhibited a 60% loss of TH positive
neurons at 27 weeks, which was similar to the S129A α-syn
rats at that time point. Rats receiving the S129D injections
did not exhibit signiﬁcant neurodegeneration at any of the
time points. Striatal DA levels were assessed by HPLC. The
HPLC analysis showed that there was a depletion of DA
levels, consistent with SN cell loss.
Azeredo da Silveira et al. [17] created an α-syn model
to observe a prevention of the phosphorylation of human
mutated α-syn which is involved in numerous neurode-
generative diseases. The study utilized the rAAV2/6 vector
with the CMV promoter. The site-directed mutations of
human A30P α-syn and hWT α-syn were at the serine
residue at position 129. The serine residue was converted to
alanine (S129A) to abolish phosphorylation or converted to
aspartate (S129D) to reproduce eﬀects of phosphorylation.4 Parkinson’s Disease
Thetwosite-directedmutationsofthemutatedhumanA30P
α-syn and hWT α-syn were compared to hWT α-syn and
mutated human A30P α-syn. Rats received two injections
within the SN. They observed a dose-dependent loss from 11
to 22% in TH-positive neurons when rats received injections
of hWT α-syn. Injection of the S129A-Mutated A30P α-
syn and hWT α-syn resulted in a dose-dependent loss of
over 70%. Whereas the S129D-mutated A30P α-syn and
human WT α-syn resulted in less neurodegeneration in the
SN then WT α-syn, rats receiving injections of hWT α-syn
with the mutated human A30P α-syn tended to display less
neurodegeneration than the WT α-syn rats.
Finally, a series of α-syn models of PD were produced
by Lo Bianco et al. [14], using an HIV-1-derived lenti-
virus, expressing a range of α-syn genes, including wild-type
humanα-syn,mutated-humanA30Pα-syn,mutated-human
A53Tα-syn,andratwild-typeα-syn.Thelargestreductionof
TH-positive neurons within the SN was observed in animals
treated with the lenti-WT human α-syn, which exhibited a
35% reduction. Rats treated with A30P α-syn and A53T α-
syn also exhibited a 33% and 24% reduction in TH-positive
neurons, respectively. Some α-syn inclusions were found in
the cytoplasm of neurites and cell bodies of surviving nigral
neurons.
Subsequent studies using genes that overexpressed glial
derived neurotrophic factor (GDNF), a protein associated
with neuroprotection of dopaminergic neurons, were unsuc-
cessful in reducing the cell loss in several of these α-syn rat
models of PD. For example, Lo Bianco et al. [23]f o u n d
that injections of a lenti-GDNF just dorsal to the SN, given
two weeks prior to bilateral injections of lenti-A30P-α-syn,
failed to reduce the loss of DA neurons as assessed by
TH immunohistochemistry. Similarly, Decressac et al. [24]
injected lenti-GDNF into the striatum two weeks prior to an
intranigral injection of rAAV2-A30P-α-syn and, in a second
study, injected rAAV2-GDNF in the striatum and just dorsal
to the SN at three weeks prior to an intranigral injection of
rAAV2-A30P-α-syn and found that these GDNF injections
failed to protect against α-syn-induced neurotoxicity in both
studies.
Lo Bianco et al. also tested the potential eﬃcacy of
using lenti-viral delivery of parkin in an α-syn rat model
of PD [25]. Parkin is a 465-amino-acid protein responsible
for protein degradation, and mutated forms of parkin
are found in about 50% of the cases of juvenile PD, an
autosomal recessive form of this disease [26]. Lo Bianco et
al. gave two groups of rats bilateral injections into the right
SN of either lenti-A30P-α-syn/lenti-YFP, or lenti-A30P-α-
syn/lenti-Parkin (with the Parkin gene being derived from a
wild-type rat). Control animals received injections of either
lenti-Parkin or lenti-YFP. A 31% reduction of TH-positive
neurons in the SN was observed in animals receiving lenti-
A30P-α-syn, whereas a 9% reduction in TH positive neurons
was observed in the SN of animals receiving lenti-A30P-α-
syn with lenti-Parkin. There was a 16% reduction in TH-
positive neurites within the striatum of the lenti-A30P-α-
syn rats. The animals receiving lenti-A30P-α-syn with lenti-
Parkin exhibited a 4% reduction in TH-positive neurites
within the striatum. In addition, animals receiving lenti-
A30P-α-synwithlenti-Parkin,asevidencedbysilverstaining,
did not show an α-syn-induced neurodegeneration, whereas
the lenti-A30P-α-syn group did. Animals receiving lenti-
A30P-α-syn with lenti-Parkin exhibited a 45% increase in
hyperphosphorylatedα-syninclusion,andlenti-A30P-α-syn
animals showed a 43% increase in hyperphosphorylated α-
syn inclusions. Similarly, Yamada et al. [4] examined the
eﬀects of Parkin on the rAAV α-syn model of PD. They
injected rAAV expressing α-syn and rAAV parkin at the same
time directly into SN and observed a decrease of cell death of
DAneuronswithintheSNandthenumberofapomorphine-
induced rotations, compared to rat injected with rAAV α-syn
alone. Clearly, the α-syn rat models of PD provide many of
the features that resemble symptoms of PD. However, most
of the models produce a relatively limited cell loss, which
provides a useful model of early PD but lacks the extensive
cell loss and behavioral deﬁcits to accurately mimic the later
stages of this disease. Early therapeutic trials in these rat
models have suggested that overexpression of the gene for
parkin, but not GDNF, may reduce TH-positive cell loss in
this model of PD.
3.4-Leucine-RichRepeatKinase 2 (LRRK2)
A second type of transgenic rat model involves the use of
LRRK2, which is a member of the ROCO protein family
and the RAS-GTPasesuperfamily. The LRRK2gene contains
both a GTPase-like domain and a kinase-like domain. An
important number of mutations in the gene have been
identiﬁed and associated with PD. Of these mutations,
G2019S has been found to be the most common [27, 28]
and is a point mutation located within the kinase domain.
Another common mutation is R1441C, in which a mutation
occurs within the GTPase domain.
Zhou et al. [21] utilized LRRK2 transgenic rats pos-
sessing the G2019S mutation. Transgenic rats were created
by crossing TRE-LRRK2 G2019S transgenic rats with CAG-
tTA transgenic rats. These investigators examined the eﬀects
of temporal expression of the human LRRK2 mutation,
using a promoter that is activated by the absence of
doxycycline. They measured the total distance and stereo-
typical movements the rats made in an open-ﬁeld maze
during a 20-minute assessment period, followed by an
addition 20-minute period, which was given 5 minutes
after an injection of amphetamine or 20 minutes after
an injection of nomifensine (an inhibitor of DA reup-
take). They found that the temporal expression of the
human LRRK2 G2019S increased the distance traveled as
well as the amount of stereotypical behavior. When given
nomifensine or amphetamine, the temporal expression of
LRRK2 G2019S signiﬁcantly reduced the amount of evoked
responses, compared to controls. In addition to the open-
ﬁeld assessments, these investigators measured intrastriatal
DA via microdialysis and found an increase in extracellular
DA in the striatum of rats receiving temporal expression
of LRRK2. However, there were no increase in the level of
DA when amphetamine and nomifensine was administeredParkinson’s Disease 5
to these rats. The researchers attributed these results to an
impairmentoftheDAtransporter(DAT)duetopreservation
of in TH-positive neurons within the SNpc, nor were there
any changes observed in the number of axon terminals in the
striatum.
Dusonchet et al. [20] produced a transgenic LRRK2
model in adult rats utilizing recombinant human serotype
5 adenovirus (RAd). These investigators compared the
overexpression of human wild-type LRRK2 to the LRRK2
G2019Shumanmutation.TheyfoundnolossofTH-positive
cellsinthehumanwild-typeLRRK2animals.However,there
was a progressive TH-positive cell loss, observed between
10 and 42 days (with a total loss of 21.4%), and a 10%
decrease in striatal TH-positive ﬁbers in G2019S LRRK2
animals.
As with the α-syn models, the LRRK2 transgenic rat
models of PD appear to provide only a modest loss of TH-
positive cells. However, there is evidence of motor deﬁcits, as
measured in the open-ﬁeld maze, when the LRRK2 G2019S
gene is activated in this transgenic rat model of PD. As such,
this model may also provide a useful tool for evaluating
potential treatments during the early stages of PD.
4. Conclusion
In this paper, we have provided an update on the various
genetic rat models of PD. Although there is considerable
variability among the studies reviewed in terms of the
types of genes and techniques used, most of these models
revealed a progressive and signiﬁcant, albeit modest, loss
of TH-positive neurons in the SNpc. As can be ascertained
from Table 1, the α-syn models show progressive cell loss,
with protein aggregation, but little evidence for consistent
motoric deﬁcits. The use of the α-syn A53T rat model did
produce signiﬁcant TH-positive cell loss (at about 60%)
and concomitant motor deﬁcits, but this occurred in only
25% of the rats receiving this mutated gene. The LRRK2
m o d e lp r o d u c e db o t hal e v e lo fc e l ll o s sc o m p a r a b l et oe a r l y -
stage PD and motor deﬁcits in the open-ﬁeld maze, but
there is no evidence of protein aggregation in these animals.
In terms of treatments, studies using transgenic PD rats
have indicated that parkin can provide a signiﬁcant level of
protection against dopaminergic neuronal loss. Collectively,
these studies indicate that the currently used transgenic rat
models of PD can provide a useful tool for the early stages
of PD, but more work is needed in developing a model
that mimics the progressive neuropathology and behavioral
deﬁcits that are observed throughout the time span of this
disease.
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